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Summary 
In Hodgkin's disease  (HD),  the  Hodgkin and R.eed-Sternberg  (HR.S)  cells  represent only a 
minute population in the diseased tissue.  The investigation of lineage derivation and clonal or- 
igin of these cells  has yielded conflicting results.  We have analyzed HRS cells micromanipu- 
lated from infiltrated tissue sections of 10 primary HD patients for rearranged V genes, extend- 
ing a previous study. Clonally related rearrangements were found in nine cases, indicating that 
HRS cells represent a dominant clone of B lineage-derived cells in at least a large fraction of 
cases of liD. Rearranged V. genes from HP.S cells carried a high load of somatic mutation, in- 
dicating that  HRS  cells  are  derived from germinal center  (GC)  cells  or their progeny.  Stop 
codons in some in-frame V gene rearrangements suggest that the HR.S ceil precursors reside in- 
side GCs, have acquired crippling mutations that prevent antigenic selection, but escape apop- 
tosis through some transforming event. 
T 
he Hodgkin and Reed-Sternberg (HRS) 1 ceils, which 
are  considered  to represent the  malignant tumor cell 
population in Hodgkin's disease  (HD), still pose riddles as 
to their origin and clonality.  In contrast to the abundance 
of tumor  cells  in  other  neoplasias,  the  HRS  cells  in  HD 
(usually ~1% of cells)  reside within  a complex admixture 
of lymphocytes,  plasma  cells,  histiocytes,  eosinophils,  and 
other  cells.  The  composition  of the  cellular  background 
and morphological criteria have led  to  the  subdivision  of 
HD into the three "classical  HD" subtypes, namely, nodu- 
lar sclerosing  (NS),  mixed cellularity  (MC),  and lympho- 
cyte depleted (LD), besides the fourth subtype, lymphocyte 
predominant  (LP)  (1,  2).  HRS  cells  of the  NS,  MC,  and 
LD categories of HD express the activation markers CD30 
and  CD15  as  detected  by immunohistochemistry  (3).  In 
the LP subtype, HRS cell variants often lack these antigens 
but express several B  cell-associated molecules, and there- 
fore are commonly accepted to be of B lineage origin (4). 
Despite considerable effort, lineage derivation and clonal- 
ity of the HRS cells in classical HD are controversial (3, 5). 
1Abbreviations used in this paper: FR, framework  region; GC, germinal  cen- 
ter; HD, Hodgkin's disease; HRS, Hodgkin and Reed-Sternberg; LD, 
lymphocyte depleted; LMP, latent membrane protein; LP, lymphocyte 
predominant; MC, mixed cellularity; NS, nodular sclerosing. 
H. Kanzler  and R. Kfippers  contributed equally to this work. 
This is mainly due to the sparseness of the HRS cells  and 
difficulties encountered in attempts to isolate these cells  (6, 
7).  Immunohistochemical  studies  yielded  conflicting  re- 
sults,  revealing B  and/or T  cell markers on HRS cells and 
occasionally also monocyte markers (3). In a recent study of 
HRS  cells  at the  level of single  cells,  expression of genes 
characteristic  of several hematopoietic lineages  was  found 
(8).  Furthermore,  Southern  blot  hybridization  and  PCR 
approaches for the detection of Ig or TCR gene rearrange- 
ments using whole tissue DNA from HD infiltrates (as suc- 
cessfully perfomed on other lymphomas) detected such re- 
arrangements  only in  a  small number of cases  (5).  These 
population-based approaches now are considered inappro- 
priate because of low sensitivity and the inherent inability 
to specifically assign  rearrangements detected to the sparse 
HRS cells  (9).  However, the demonstration of clonal nu- 
merical  chromosome  aberrations  in  HRS  cells  and  EBV 
genome studies suggest a monoclonal origin of HRS cells 
(10-12). 
Recently, we overcame the problems associated with the 
small  number  of HRS  cells  by isolating individual  HRS 
cells  from frozen sections by micromanipulation  and  ana- 
lyzing them by amplification of gene rearrangements (13). 
Using this approach, the HP,.S  cells in four cases of HD (2 
ofMC, 1 of NS and 1 of LP subtype) were found to repre- 
sent a single clone and to originate from the B lineage, be- 
cause Ig V  gene rearrangements are restricted to B  lineage 
cells and highly specific for a B  cell clone (13,  14).  Single- 
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the analysis of classical  HD, but with differing results (15, 
16;  see  Discussion).  P,.oth  et  al.  (15)  isolated  HR.S  cells 
from suspensions of LN from 13 HD patients (12 with clas- 
sical HD) and failed to detect any V H gene rearrangements.  Age  Disease  Disease 
Hummel et al. (16) suggested that HKS cells carrying poly-  Patient*  (yr)/sex  subtype  stage* 
clonal Ig V  gene rearrangements in a large fraction of cases 
might exist. 
In our previous studies,  only four HD  cases  (and only  1  18/F  NS  II B 
three  of the  "classical"  category)  were  analyzed,  leaving  2  51/F  NS  II A 
open whether clonality and B  lineage derivation are com-  3  28/F  NS  III A 
mon features of liD (13,  14).  Therefore, we have now in-  4  17/F  NS  IIB 
vestigated a larger number of cases  to  determine whether  5  27/F  NS  II A 
HRS  cells  in  general  represent  a  clonal population  and  6  36/M  NS  I B 
originate from B  lineage cells.  Clonal Ig  gene rearrange-  7  36/M  MC  II A 
ments were  identified in most  cases,  and  their  sequence  8  29/M  MC  HI B 
analysis allowed us to determine the stage of maturation of 
the B  cell from which the tumor clone arose.  9  18/M  MC  II A 
10  19/M  MC  I A 
Table 1.  Case  Description of 10 Patients Sufferingfrorn Primary 
Hodgkin' s Disease Whose HRS Cells Were Analyzed for Ig Gene 
Rearrangements 
HRS cells 
CD30~  CD155  EBVll 
+  +  - 
+  +  + 
+  +  -- 
+  +  - 
+  +  + 
+  -  + 
+  +  - 
+  +  + 
+  +  - 
+  +  + 
Materials  and  Methods 
Tissues and Clinical Data.  Clinical features of the HD patients 
are summarized in Table 1. Biopsy specimens of 10 cases of classi- 
cal HD were chosen from the files of the LN registery at the Pa- 
thology Department at  the University of Cologne. All biopsies 
were LN taken out for primary diagnosis of liD. A tonsillar spec- 
imen from a child suffering form chronic tonsillites was used as 
control in some experiments. 
Immunostaining and Micromanipulation.  Immunohistochemical 
staining procedures  using antibodies against CD30, CD20, Ki67, 
LMP1  (Dako, Hamburg, Germany), CD15 (Becton Dickinson & 
Co., Mountain View, CA), and CD3 (Ortho Diagnostic Systems, 
Inc., R.aritan, NJ) were as described in our previous publications 
(18, 19). The stained sections  were  overlaid  with Tris-buffered 
saline (TBS), and single cells were isolated under the microscope 
(Olympus, Hamburg, Germany; 600￿  with the help ofmicropi- 
pettes fixed to hydraulic micromanipulators (see Fig. 1)  (18, 19). 
Isolated  cells were  transfered  into 20  p,1  PCR buffer  (20  mM 
Tris-HC1,  pH 8.4,  50 mM KCI)  containing 1 ng/l~l 5S rR.NA 
(Boehringer  Mannheim  GmbH,  Mannheim,  Germany)  and 
stored  at  -80~  Single  CD30 + HR.S  cells and CD3 + T  cells 
were obtained from adjacent sections of the same specimen. In a 
few experiments (see Table 2, experiments 2a and 8), single man- 
tle zone B cells were micromanipulated from a Ki67 stained ton- 
sillar section of another individual. The isolated cells were coded 
and analyzed in a blinded fashion. In the repeat experiments,  sep- 
arate  sections  were  analyzed  following the  protocol  outlined 
above. 
Sorting of lgD  + and IgA  + Peripheral  Blood B Cells.  PBMC  were 
isolated  by Ficoll gradient centrifugation (PAQUE R.; Pham~a- 
cia/LKB, Uppsala,  Sweden).  B cells were enriched by magnetic 
cell sorting using the MACS system and anti-CD19 beads (Mil- 
tenyi Biotec,  Bergisch-Gladbach,  Germany)  (20). The  CD19  + 
fraction was stained by a combination of anti-CD20-PE (Becton 
Dickinson & Co.) and anti-IgD-FITC (Southern Biotechnology 
Associates, Birmingham, AL) or anti-lg h-PE (Becton Dickinson 
& Co.) and anti-Ig K-FITC (Becton Dickinson & Co.) antibod- 
ies. After  washing with  PBA  (PBS, 1%  BSA,  0.02%  sodium 
azide), single IgD+CD20  + and single IgK  + cells were isolated by 
fluorescence-activated  cell  sorting using a  FACS  |  440  (Becton 
Dickinson & Co.). Dead cells were excluded from the analysis by 
HR.S cells in the cases analyzed  were negative for CD20 and CD3 ex- 
pression as determined by imnmnostaining. 
*All biopsies were cervical LN, except for one axillary LN biopsy for 
patient 4. 
*According to the Ann Arbor classification  system (17). 
~Presence (+) or absence (-) ofCD30 + or CDI5 + cells determined by 
immunostaining. 
I(Presence (+) or absence (-) of EBV detected by staining  with an anti- 
body against  LMP 1. 
staining with propidium iodide. Single cells were sorted into 0.5-ml 
microtubes  containing 20  ILl  PCP-  buffer  supplemented with 
1 ng/p~l 5S rR.NA (Boehringer Mannheim GmbH) and stored at 
-  80oc. 
Single-Cell PCR.  Rearranged Ig genes  were  amplified  from 
single cells using the seminested PCR. approach  and V-gene fam- 
ily--specific primers  together with JH and JK primers  as described 
previously (18, 19). Briefly, single cells in 20 jxl PCR. buffer were 
incubated with 0.25  mg/ml proteinase  K for  1 h,  subsequently 
inactivating  the enzyme at 95~  for 10 min. In the same tube, the 
first amplification round was carried out with 20 mM Tris-HC1, 
pH  8.4,  50  mM  KCI,  2.5  mM  MgCI2, 100  IxM  each  dATP, 
dGTP, dCTP, and dTTP, 6.9  nM each Vt~, VK, 3'Jw, and 3'JK 
primer (19), and 1.25 U ofTaq DNA polymerase (GICBO BRL, 
Gaithersburg,  MD) in a total  volume of 50 Ixl. The PCR con- 
sisted of one cycle of 95~  for 2 min, 65~  for 5 min, and 72~ 
for 1 rain, followed by 34 cycles of 95~  for 1 min, 59~  for 30 s, 
and 72~  for 1 min, followed by 72~  for  5 min. Enzyme was 
added during the 5-min incubation at 65~  A 1-1xl aliqout of the 
first round was reamplified in a second round in separate reactions 
for  each  of the six VH  and six V K family-specific  primers.  The 
50-1xl reaction mix of the second PCP~ contained 20 mM Tris- 
HC1, pH  8.4,  50  mM  KC1, 2.5  mM  MgCI:  (1,5 mM for  V, 
primers),  100  I~M  of each  dATP,  dGTP,  dCTP,  and  dTTP, 
0.125  IxM of one of the V  H or V~ primers  together with 0.125 
jxM of the respective  5'Jt~ or 5'J, primer mixes, and 1.25 U Taq 
polymerase  (GIBCO BP,.L). The cycle progam was the same as 
for the first round except that the annealing temperature in the 
first cycle was 68~  and the annealing temperature in the follow- 
ing 44 cycles was 61~  (65~  for VH3 and VH4). Amplification 
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single  HRS  cell. HD-infiltrated  LN 
biopsy  with  a  CD30  +  HRS  in  the 
middle of the picture (a) before and (b) 
after  isolation.  Note  that  the  sur- 
rounding cells were  not disturbed by 
the  micromanipulation.  Frozen  sec- 
tion, anti-CD30 antibody staining, he- 
matoxylin counterstain, ￿ 600. 
was performed in a thermal cycler (model 480 Perkin Elmer, Fos- 
ter City, CA, or Trio-Thermoblock; Biometra, G6ttingen, Ger- 
many). An 8-1xl aliquot of the reaction mix was analyzed on a 2% 
agarose  gel. The primers used have been published elsewhere (19). 
The following modifications were introduced: a new JH3-specific 
primer (5'-GAC GGT  GAC CAT TGT CCC  TTG  GCC-3') 
was  used in the  second round of amplification and primer 5'Jiq 
1,3,4,5  was modified to  5'-GAC GGT GAC CAG GGT KCC 
CTG  GCC-3'.  In some  experiments,  V.  gene  family-specific 
framework region (FR) I primers (19)  in the first round of PCR 
were exchanged for a set ofVH FRII primers (Kanzler, H., R. Kip- 
pers,  M.-L.  Hansmann, and K.  Rajewsky,  unpublished results). 
The  Vxl  rearrangement in patient 2  was  amplified with  a  Vxl 
family--specific primer and a set of nested J￿  primers (Kippers, R., 
M.-L. Hansmann, and K. Rajewsky, unpublished observation). 
Sequence Analysis.  PCR  products  were  gel  purified  from 
2.5%  agarose  gels  using a  gel  extraction kit  (Qiaex  II; Qiagen, 
Hilden, Germany) and directly sequenced. Cycle sequencing was 
performed using the Ready Reaction DyeDeoxyTerminator cy- 
cle sequencing kit (Perkin Elmer, Foster City, CA) and automatic 
sequencing (Applied Biosystems/Perkin Elmer)  or  the  ds  cycle 
sequencing system (GIBCO BRL)  following the instructions of 
the  manufacturer.  Sequencing primers were  the  same as  in the 
second  round  of amplification.  DNASIS  software  (Pharmacia/ 
LKB) and the GenBank data library (release  92) were used to an- 
alyze the V gene sequences. 
Results 
PCR Analysis of Isolated FIRS Cells.  Single  CD30 +  HRS 
cells were micromanipulated from HD-infiltrated frozen tis- 
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PCR products  Rearrangements 
Cells 
Patient  Experiment  positive  Total  Sequenced*  Repeated  Unique 
3 ~ 
4 
5~ 
6* 
la  3/9  4  3  2 V~4 
1V~3 
lb  10/20  14  14  10 V~4 
1V~3 
Control￿82 
2a  9/20  12  12  3 V~al 
9 V~3 
2ar  2/9  2  2  2 Val 
2br  4/18  4  4  4 Val 
3a  8/20  8  7  7 VK2 
3b~  2/9  2  2  2 V~2 
4  15/21  17  16  14 VH3 
5a  4/20  8Jr  6  2 VH3 
5b  3/13  3  3  3 V.3 
5c  2/10  2  2  2 VH3 
6a  8/20  10  10  7 V~3 
6b~  2/9  2  2 
7~  7a  8/9  14  14 
7b  5/10  7  6 
8  8  13/18  23  23 
2 V~3 
6 VHI 
8 V~3 
3 VH1 
3 V~3 
12 VH3 
5 VH3 
3 V~l 
3 V~3 
1 VH3 
1 V~l 
l  V~2 
1 VH3 
1 V~2 
1 VH4 
1 VH61J 
1 V~l 
1 V~4rl 
2 VH3 
1 VK1 
9  9~  0/17 
10  10a  9/20  13  11  2 VH3  1 VHI 
3 VH3 
2 VH4 
2 VK2 
1 VK3 
10b  9/23  9  9  8 VH3  1 VK1 
10c  2/9  2  2  2 VH3 
B cells  72/89  158  83  Multiple** 
T  cells  6/132  7  7  Multiple** 
HRS cells were analyzed together with B cells and T cells as controls. The number of cells analyzed and cells yielding at least one PCR product are 
indicated. Repeated rearrangements  indicates clonally related rearrangements; unique rearrangements  are rearrangements amplified only once and not re- 
lated to any other sequence. The same repeated rearrangements were detected in the HRS cells in the repeat experiments for patients 1-3 and 5-7. 
For patient 10, the VH3 gene rearrangement amplified twice in experiment 10a was different than the VH3 rearrangement in experiments 10b and 
10c, whereas identical VH3 gene rearrangements were obtained in experiments 10b and 10c. 
*Among 8 PCR products from HRS cells not sequenced were one VK3 gene rearrangement (experiment la), one VK2 gene rearrangement (experi- 
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PCR  (Fig.  1).  The panel  of cases analyzed consisted of 10 
primary HD patients, 6 of the NS and 4 of the MC subtype 
(Table  1).  HRS cells did not detectably express the CD20 
and  CD3  markers.  In 50% of the patients,  the presence  of 
EBV could be detected by latent membrane protein (LMP) 
1 immunostaining  (Table  1).  In 5  of the  10 cases,  a repeat 
experiment was carried out. Cases 5 and 10 were examined 
three  times  (Table  2).  As  negative  control,  single  T  cells 
micromanipulated on the same day as the HRS cells from a 
CD3-stained  adjacent  section  of the  same  LN  were  ana- 
lyzed together with the HRS cells  in a blinded fashion. As 
positive control, single IgD + peripheral blood B  cells  were 
sorted by flow cytometry and analyzed in parallel with the 
HRS and T  cells  (Table 2, in experiments 2a and 8, B  cells 
micromanipulated  from  a  tonsillar  section  were  used). 
From 132 T  cells  analyzed, 7  Ig gene rearrangements  were 
obtained.  These  originated  most  likely  from  cellular  or 
other contamination during the micromanipulation proce- 
dure. V~ and/or V~ PCR products were obtained from 72 
of 89 control B cells (including 74 FACS|  B cells,  of 
which 66  (89%)  yielded at least one product),  demonstrat- 
ing the high efficiency of the PCR. strategy. The Ig V gene 
sequences from control B  cells  and T  cells were unique and 
clonally  unrelated  to  V  gene  sequences  from  HRS  cells. 
The  finding  of identical  Ig gene  rearrangements  in  HRS 
cells  in  repeated  experiments  (see  below)  further  demon- 
strated the validity of the single-cell approach chosen. 
HRS Cells  Harbor Clonal (g Gene Rearrangments.  From  each 
HD patient,  between  17 and 52 individual HRS cells  were 
analyzed for Ig gene rearrangements  (Table 2). From a total 
of 304  HRS  cells,  118  yielded  amplification  products.  In 
the nine cases in which rearrangements were identified,  the 
efficiency of amplification from the H1KS cells varied from 
20 to 89% positive cells in different experiments.  Direct se- 
quencing  of the  PCR  products  confirmed  that  the  H1KS 
cells  indeed  carried  rearranged  VH  and/or  VL  gene  rear- 
rangements  (Table 2).  Furthermore,  the vast majority of Ig 
V  gene rearrangements gained from HIKS cells  of the same 
case were clonally related, with one possible exception (see 
below). 
No  Ig  gene  rearrangements  were  amplified  from  the 
HIKS cells  from patient  9,  even  when  we  exchanged  the 
V,  gene  family-specific FRI primers  in  the first round  of 
PCR by a set of FPdI primers  (Table 2).  The FRII primer 
set  was  used  to  detect  potential  VH  gene  rearrangements 
that could not be amplified with VH FRI primers  (e.g., be- 
cause of somatic mutations;  see Discussion).  The V,  FR.II 
primer set or a group ofV~ gene-specific primers were also 
used  to investigate  HRS  ceils  from other patients.  Except 
for the amplification ofa clonal Vxl  gene rearrangement in 
HRS cells from patient 2, this did not lead to the detection 
of Ig gene rearrangements beyond those  already identified 
(Table 2 and data not shown). 
In the  case  of patients  1-3,  5-7,  and  10,  repeat  experi- 
ments were performed.  Identical Ig V  gene rearrangements 
were detected, with one exception (patient  10, see below). 
For patient  5  (the  case  with  only 20%  amplification  effi- 
ciency),  a  third  experiment  was  carried  out  yielding  the 
same  results  as  in  experiments  5a  and  5b.  The  results  in 
repeat experiments  10b and  10c differed from those in ex- 
periment  10a.  Whereas  in  experiment  10a  a  number  of 
clonally unrelated Ig V gene rearrangements were obtained 
besides  two HRS cells  harboring a  related VH3 gene rear- 
rangement,  HRS cells  in experiments  10b and 10c showed 
a VH3 gene rearrangement differing from the one in exper- 
iment  10a  but  identical  between  the  two  repeat  experi- 
ments. 
Sporadically,  HR.S ceils  also gave rise to Ig V  gene rear- 
rangments  that  were  not  related  to  the  clonal  rearrange- 
ment(s)  carried by the majori  W of HRS cells  from the re- 
spective  case  (Table  2).  These  "unique"  rearrangements 
were  detected  in  11  out of 304  (3.6%)  of HRS  cells  ana- 
lyzed (the  unique  Ig gene rearrangements  obtained  in  ex- 
periment  10a are discussed below). T  cells  included as con- 
trols for cellular or other contamination gave rise to Ig gene 
rearrangements  with  about  the  same  frequency  (6  out  of 
132 [4.5%] ofT cells analyzed; Table 2), suggesting that the 
unique  Ig gene  rearrangements  amplified  from HRS  cells 
were  also  due  to  cellular  or other contamination.  Indeed, 
the unique  Ig gene rearrangements  from HRS and T  cells 
were either unmutated  or harbored between  0.5 and 6.3% 
mutation  (on the  average  2.5%  for mutated  rearranged  V 
genes).  Because  naive  B  cells  with  unmutated  V  genes  as 
well as memory B  cells  (harboring on the average 4% mu- 
tation) are present in human LNs (18, 21, 22), the mutation 
ment 3a), one VH2 gene rearrangement (experiment 4), one VH4 and one VK3 rearrangement (experiment 5a), one V~3 rearrangement (experiment 
7b), and two VH4 gene rearrangements (experiment 10a). 
:~HI<S cells from patient 2 (27 HtkS cells), patient 3 (11 HP,.S cells), patient 5 (7 HIkS cells), patient 6 (10 HP,  S cells), and patient 7 (11 HRS cells) 
were analyzed for Ig V  a gene rearrangements. Because rearranged Vx genes from the HIR.S cells of  patient 2 only were amplified, data from this case 
only are included. 
~Vw gene primers annealing to the FP,  II were used instead of the V  H FP,.I primer set (in experiment 9, 8 HRS cells were analyzed using the VH FP,  I 
primer set and 9 cells using the V  H FRII primer set). 
IJUnique rearrangements (two sequenced, two not sequenced) originate from one cell. 
￿82  2 and 9 B  cells and 3 and 10 T cells were analyzed in each experiment. The number of cells indicated represents a summary of all control 
experiments. 
**Clonally unrelated VH and V~ gene rearrangements of various V gene families were detected. In B cells, members of all V•  and V~ gene families 
were amplified except for V~6. None of 90 sequenced Ig gene rearrangements obtained from B cells or T cells was clonally related to a repeated se- 
quence from an HRS cell. For 4 PCIK  products, sequences could not be determined because we obtained double sequences, or PCP,- products were 
lost upon purification. 71 PCP- products from B cells were not sequenced because the V genes belonged to other V gene families than those of the 
HRS cells of  the respective patient. 
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CDR  I  CDR  II 
26  28  30  31  33  34  35  35b  40  50  51  53  56  57  59  60  62  67  69  76  78  81  82a  B2b  83  89  90 
V4-31  GGT  TCC  AGC  AGT  GGT  TAC  TAC  AGC  CAC  TAC  ATC  TAC  AGC  ACC  TAC  AAC  TCC  GTT  ATA  AAC  TTC  AAG  AGC  TCT  ACT  GTG  TAT 
Pat.#1  A--  C  ....  G  --A  -Ac  --A  ....  C-  TT-  G  ....  t  --~  -At  -G-  -G-  -C-  C  ....  g  -Ag  GC-  --G  --C  -A-  -A-  T  ....  a  -T- 
Pat. #I  A--  C  ....  G  --A  -Ac  --~  --~  -C-  TT-  G  ....  t  --~  -At  ....  G-  -C-  C  ....  g  ~Ag  GC-  --G  --C  -A-  ~A-  T--  A--  -T- 
b.) 
CDR  I  __  CDR  II 
25  30  31  33  34  38  40  49  ~-  53  55  62  66  68  69  70  74  75  76  ~7  79  80  82a  85  89  94 
V71-5  TCT  ACT  AGC  C~2T  GTG  CGA  GCT  GGA  ATC  GGC  C43T  AAG  AGA  ACC  ATT  ACC  TCC  ACA  AGC  ACA  TAC  A~G  AGC  GAG  GTG  GCA 
Pat.#2  ....  G-  -ct  AA-  A-A  --c  --c  --g  G--  -C-  --c  C--  G--  T  ....  c  C  ....  g  --c  -A-  --t  -C-  C--  -T-  --C  A-A  A-- 
e.) 
CDR  I  CDR  II 
25  28  30  31  33  45  46  50  51  52a  55  56  57  58  59  60  62  73  75  76  79  81  84  89  94 
V3-30  TCT  ACC  AGT  AGC  GGC  CTG  GAG  GTT  ATA  TAT  AGT  AAT  AAA  TAC  TAT  GCA  TCC  AAT  AAG  AAC  TAT  CAA  GCT  GTG  AGA 
Pat,#4  --c  -At  G-g  -A-  -A-  --a  C--  A  ....  t  --c  -A-  --A  -C-  --t  -C-  -T-  --t  --c  G  ....  G  -T-  --C  -T-  --a  -C- 
d.} 
CDR  I  CDR  II 
25  28  29  30  35  41  44  49  52  52b  52c  53  54  55  57  58  60  61  63  64  74  75  77  78  79  81  82  82a  82b  83  84  85  88  89  93  94 
9-1  TCT  ACT  TTC  AGT  AGC  CCA  GGG  GGC  AA.%  AAA  ACT  GAT  C43T  GGG  ACA  GAC  GCT  GCA  GTG  AAA  TCA  AAA  ACG  CTG  TAT  CAA  ATG  AAC  AGC  AAA  ACC  GAG  GCC  GTG  ACC  ACA 
Pat,#5  ~--  G--  G-t  -AG  -At  ~-g  --t  -~t  --g  G-~  T  ....  A  --c  -C-  --t  --G  T--  CAT  --a  G  ....  c  -C-  --c  T-C  -T-  GTC  --C  -TG  -A-  C--  -G~  --C  -G-  A~T  G  .... 
e.) 
CDR  I  CDR  II 
25  30  31  32  41  44  48  53  54  56  57  61  62  63  65  72  75  76  81  82  82a  82b  83  89  91  94 
VI-8  TCT  ACC  AGT  TAT  ACT  GGG  ATG  AAC  AGT  AAC  ACA  CAG  AAG  TTC  GGC  AAC  ATA  AGC  GAG  CTG  AGC  AGC  AGA  GTG  TAC  AGA 
Pat, #7  ---  CA-  GAC  C--  C  ....  C  C  ....  G  -C-  G  ....  t  G  ....  a  --t  -A-  GT-  -C~  -C-  --a  A--  -C-  ~-G  -Ag  --c  -T  .... 
f.} 
CDR  II  CDR  I  CDR  I[ 
25  50  53  57  91  94  25  30  31  34  58  59  61  78  79  82a  88  91  94 
V3-11  TCT  TAC  AGT  ATA  TAC  AGA  l-gill  TCT  AGT  AGC  ATG  TAC  TAT  GAC  CTG  TAT  AAC  GCT  TAC  AAA 
Pat,#8  ---  --~  T--  -G-  C-A  ---  Pat.#8  .....  A  --t  -Ga  -GG  --c  -T-  G--  A  ....  t  A--  ~  --- 
g.} 
CDRI  CDR  II 
32  35  36  52a  55  56  58  63  74  75  82a  82b  84  94 
V3-9  TAT  CAC  TGG  TGG  GGT  AGe  Csud2 GTG GCC  AAG  AAC  AGT  GCT  AAA 
Pat. #I0  ---  A--  -_~  -~  A--  TAT  -A-  --x  ---  A  --C  -T-  -G- 
Figure 2.  Comparison of V  H region gene sequences from HRS cells to the most homologous  germline genes. Nucleotide  sequences of V  H region 
genes amplified from individual HRS cells of(a) patient 1, (b) patient 2, (c) patient 4, (d) patient 5, (e) patient 7, Or) patient 8, and (g) patient 1{) are com- 
pared with the most homologous germline genes. Only the first and the last codon and those codons of the V. genes are shown that differ from the re- 
spective germline genes. Dashes indicate sequence identity. Replacement  mutations are indicated by uppercase letters, silent mutations by lowercase let- 
ters. In cases in which two point mutations were present in a codon, it is assumed that the mutation that lead to a replacement (independent whether it 
occured first or second to the other mutation)  occured first. Three mutations in a codon are not classified  as replacement or silent mutation separately, 
Underlined codons mark stop codons originating from mutation. The upper sequence from patient 1 (a) was amplified frora seven HRS cells, the lower 
sequence from five HRS cells, indicating intraclonal diversity in this patient. ￿  marks a nucleotide not clearly readable on the sequence gels, A deletion 
of codons 75-82a in the V3-9 gene rearrangement in HRS cells from patient 10 (g) is indicated by A. Codons are numbererd according to Kabat et al. 
(23). For reference ofV  H germline genes see Matsuda et al. (24) and Berman et al. (25). Sequence data of the clonally related Ig V gene rearrangements 
from HRS cells have been deposited in the GenBank data base under accession number Z77316-Z77331.  All other sequence data are available from the 
authors upon request. 
pattern  found  for  the  unique  lg  gene  rearrangements  is 
compatible with a derivation of those products from poly- 
clonal, surrounding t3 cells. They thus most likely represent 
cellular contamination during the micromanipulation pro- 
cedure.  This is strongly supported by the  fact that  the  se- 
quence  characteristics  of the  clonal  gene  rearrangements 
carried  by  the  HRS  cells  distinguish them  from  those  of 
normal B  cells (see Discussion). 
Rearranged V  Genes in HRS Cells Have Been Affected and 
Sometimes Silenced by Somatic Mutation.  The  sequences  of 
the  clonal  VH  gene  rearrangements  amplified  from  HRS 
cells are shown in Fig. 2  and the results summarized in Ta- 
ble  3.  The  VH  gene  sequences  carried  between  5  and  45 
nucleotide  differences  (2.2-19.6%)  compared  with  the 
most  homologous  germline  genes.  The  vast  majority  of 
these nucleotide substitutions can be reliably assigned to so- 
matic  mutations because  most  human  VH  genes  are  now 
known  (24,  28).  In this study, this is evidenced by the se- 
quence analysis of V,  genes amplified from  naive IgD +  B 
cells  (which  are known  to  carry unmutated V  genes)  (21, 
22, 29)  for control. Among 55 V,  genes amplified from B 
cells from two donors, 48 were  100% homologous to pub- 
lished germline genes.  Seven sequences harbored between 
one and eight nucleotide differences (on the average three 
to  four  differences)  to  the  most  homologous  germline 
genes  (R.  Kiippers, H.  Kanzler, M.-L.  Hansmann, and K. 
Rajewsky,  unpublished observation).  That  the  HRS  cell- 
derived V  gene rearrangements have indeed been subject to 
somatic hypermutation is further confirmed by the pattern 
of nucleotide substitutions. A  striking similarity to  nucle- 
otide  substitution  preferences  found  for  somatically  nm- 
tated mouse Ig passenger transgenes was observed (Table 4) 
(for review see reference 30). 
Some  of the  clonal V<J~ sequences from HRS  cells also 
carried  mutations  (unambigious in  these  cases  because  all 
human VK  genes  have  been sequenced)  (26)  while  others 
did  not.  We  tentatively  attribute  the  absence  of somatic 
mutation in the latter to the particular genomic structure of 
the  human V K gene locus that  allows the presence  of un- 
mutated rearranged V~ genes in a B  cell with a somatically 
mutated V H gene rearrangement (see Discussion) (31). 
In the HRS  cells from patient 1, we found evidence for 
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V H  VL 
Percentage of  Percentage of 
Patient  V  H family  Vtt gene  mutation  In-frame*  V L  family*  V L gene  mutation  In-flame* 
1  4  V4-31  14.4  -  3  L6  7.1 
2  1  V71-5  13.0  +-~  3  A27  0 
1  LV122  9.3 
3  2  A17  0 
4  3  V3-30  11.8  + 
5  3  9-1  19.6  + 
6  3  L6  0 
7  1  V1-8  13.0  +  3  A27  0 
8  3  V3-11  2.2  -  1  L8  3.1 
3  1-9III  5.8  +ll  3  L2  1.6 
10  3  V3-9  5.8  +in 
+ 
+11 
I 
+ 
Clonal sequences  from HRS cells are compared with the most homologous gemaline  genes (24-27). 
In patient 1, evidence for intraclonal diversity of the VH4 gene rearrangement was found. 
*Out-of-frame rearrangement (-); in-frame rearrangement (+). 
:~All V light chain gene rearrangements  are V, gene rearrangements  except for a Val gene  rearrangement in patient 2 (LV122) (27). 
~V71-5 is a pseudogene with a defective splice site. 
IIIn-frame  rearrangements  that are nonfunctional because a stop codon was introduced by somatic mutation. 
￿82 H gene rearrangement with a 27-bp deletion in FRill and stop codons in FRII and CDRII. 
intraclonal diversification of the  V H  gene  rearrangement 
with identical substitutions at four positions of the V  gene 
in 5  of the  12 HRS cells (Fig. 2).  In all other patients the 
clonally related V  gene  rearrangements did  not show  se- 
quence variation. In patient 4,  1 of 14 otherwise identical 
HRS cells carried a single base substitution. The absence of 
deletions or insertions in the clonal sequences except for a 
27-bp deletion ofcodons 75-82a of the VH gene rearrange- 
ment in HRS cells from patient 10 contrasts previous stud- 
ies in which we  detected aberrant V  gene rearrangements 
in four of seven VH  region genes  (13,  14).  Three  of the 
four V H gene rearrangements with deletions and insertions 
were  derived from  two  relapse  patients who  had  under- 
gone therapy before.  This may indicate that deletions and 
insertions in  rearranged  V  genes  occur  in  the  course  of 
therapy (32, 33). 
Among the  eight  clonally related  VH  gene  rearrange- 
ments in the collection, the rearrangements from patients 4, 
5, and 7  could potentially be translated into protein (Table 
3). The VH1 gene in patient 2 was also rearranged in-frame, 
but because the most homologous V71-5 germline gene is 
a pseudogene (because of a mutated splice site outside the 
region amplified in our study),  functionality of that  rear- 
rangement is unclear. Overall, the frequency of potentially 
functional Ig gene rearrangements was low in HRS  cells. 
In patient 1, only an out-of-frame V H gene rearrangement 
was detected. The 1-9III VH3 gene rearrangement in patient 
8 and the V3-9 VH3 gene rearrangement in patient 10 were 
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rearranged in-flame but rendered nonfunctional  because of 
stop  codons introduced by somatic  mutation (Fig.  2  and 
Table 3).  A  stop  codon most likely derived from somatic 
mutation was  also found in the  in-frame LV122  Va  gene 
rearrangement in patient 2. 
Table 4.  Nucleotide  Substitution Preferences of Somatic Mutations 
in HRS Cells 
To  Frequency of nucleotide substitution 
From  T  C  A  G 
T  -  0.074  0.033  0.041 
(0.068)  (0.040)  (0.022) 
C  0.123  -  0.057  0.090 
(0.155)  (0.019)  (0.036) 
A  0.086  0.086  --  0.115 
(0.084)  (0.055)  (0.151) 
G  0.016  0.079  0.201  - 
(0.033)  (0.118)  (0.219) 
Nucleotide substitutions  were calculated  from 244 point mutations car- 
fled by the clonal Ig gene rearrangements amplified from HRS  cells. 
Numbers in brackets represent the frequencies of nucleotide substitu- 
tions characteristic for somatic hypermutation reported by Neuberger 
and Milstein (30). Discussion 
HRS  Cells in  Classical HD Are B  Lineage Derived and As a 
Rule Represent a Dominant  Tumor Cell Clone.  In  9  out  of 
the  10 cases analyzed in this study, HRS cells  carried rear- 
ranged V. and/or VL genes, indicating their B  lineage ori- 
gin.  Furthermore,  the V  gene rearrangements of individual 
HP.S cells from a given patient were clonally related.  These 
findings are in agreement with our previous observation of 
an  expanded  HR.S  cell population  with  clonally related  V 
gene  rearrangements  in  two  cases  of MC  HD  and  one  of 
NS HD  (13,  14).  We conclude that classical  HD in most if 
not all  cases is  characterized by the  outgrowth  of a  domi- 
nant clone of HRS cells.  Recent combined fluorescence in 
situ hybridization and imnmnophenotyping studies by We- 
ber-Matthiesen et al.  (10)  and DNA content and interphase 
cytogenetics investigations by Inghirami et al.  (34)  also sup- 
port the clonal nature of the HP, S cells. 
However, the finding of clonal, B lineage-derived HR.S 
cell populations is in conflict with the work of other groups 
who also investigated HR.S cells  in classical  HD on the sin- 
gle-cell level.  The failure  ofRoth  et al.  (15)  to  detect V H 
gene  rerarrangements  in  HR.S  cells  from  any  of 13  HI) 
cases  (including  12  classical  HD  cases)  could result  from a 
technical difference between  their work and ours,  namely, 
the more stringent hybridization conditions that were used 
in their PCR  analysis. As most V H gene rearrangements  in 
HRS cells carry a high load of somatic mutations (Table 3), 
nmtations  at  the  sites  of primer  binding  might  have  pre- 
vented  successful  amplification  of such  rearrangements  in 
the  work  of Roth  et  al.  (15).  In  another  recent  article, 
Hummel et al.  (16)  reported on HRS cells  harboring poly- 
clonal  VH  gene  rearrangements  in  6  of 12  cases  of HD. 
Both polyclonal and clonal populations  of HRS cells  were 
present in three further cases,  and in only three cases,  HP,  S 
cells  represented a single tumor clone. However, these ini- 
tial findings were later partly corrected (35).  In a reanalysis 
of the cases previously classified as polyclonal, HR.S cells  in 
2 cases now turned out to carry clonally related V  gene re- 
arrangements  (we  analyzed  one  of these  cases  in  parallel 
with an identical result)  (36).  In two cases,  polyclonality of 
HR.S cells  was again found; lack of material  prevented  re- 
analysis  of the  two  remaining  cases  (35).  Given  this  con- 
fused situation,  the work of Hummel et al.  (16, 35)  neither 
supports  nor argues  against the present  data.  Furthermore, 
the relevance  of the study by Hummel et al.  for a charac- 
terization  of clonality and lineage  derivation  of HRS  cells 
in  typical cases of classical  HD  is  unclear,  because  it is  re- 
stricted  to  a  small  subset  of cases  of classical  HD  (~10- 
15%)  (3),  namely, those in which the HRS cells  express the 
B cell antigen CD20 (37-39).  In our analysis,  cases of classi- 
cal HD lacking expression of CD20 were analyzed (Table  1). 
The  HR.S  cells  from one patient  in  our collection  (pa- 
tient  10)  carried a number ofclonally unrelated V  gene re- 
arrangements in one of three experiments  (Table 2, experi- 
ment  10a).  Reevaluating  the  histological  section  used  in 
experiment  10a, we recognized that the CD30 + cells were 
smaller  than  typical  HRS  cells.  It  is  known  that  EBV- 
infected  B  cells  in  infectious  mononucleosis  can  express 
CD30 and have an HRS cell-like morphology (40).  Thus, 
a possible explanation for the clonally unrelated V gene re- 
arrangements  amplified  from  CD30 +  cells  in  experiment 
10a  is  that  we  mistakenly  isolated  CD30 +  EBV-infected 
bystander B cells  (two of which happened to be clonally re- 
lated).  Unfortunately, presence of EBV could not be deter- 
mined in the region of the LN from which cells  micronla- 
nipulated  in  experiment  10a  were  derived.  However,  as 
revealed  by the  repeat  experiments  10b  and  10c,  this  pa- 
tient also harbored a dominant clone of HRS cells  (Table 2). 
In  1 of the  10 patients  (patient  9),  we  could not detect 
any VH or VK gene rearrangement in HRS cells using either 
the standard FRI VH and VK primer sets or a set ofFRII V H 
and V~ primers  (Table 2, experiment  9).  This failure could 
be due to somatic mutations at the primer binding sites.  Al- 
ternatively,  the  HRS cells  of this patient  were not derived 
from B  lineage  cells.  The  occasional  expression  of T  cell 
antigens on HRS cells  is compatible with a T  cell origin of 
HRS cells  in a minor fraction of liD  (3). 
HRS  Cells Seem to  Ort[~,inate  from  Germinal Center (GC) B 
Cells  Tkat  at  Least  in  Part Acquired  Cripplit(~, Somatic Muta- 
tions Preventing  Antigenic Selection.  All  clonally  related  VH 
genes anaplified from HtLS cells  in this study showed mul- 
tiple  nucleotide  substitutions  when  compared  with  the 
most homologous germline genes (Fig. 2 and Table 3) and, 
as discussed in the Results section, most of these nmst have 
been introduced by the process  of somatic hypemmtation. 
The  finding  of unmutated,  out-of-frame  V~  gene  rear- 
rangements in patients  3  and 6  does not exclude that these 
cases  also  harbor  somatically  mutated  rearranged  V  genes 
that  we  failed  to  amplify.  Deletion  of the  K enhancers  in 
k-expressing B  cells  likely prevents somatic hypernmtation 
of retained  VcJ  K joints,  so  that  unmutated  V,  gene  rear- 
rangements can be amplified from B  cells  carrying nmtated 
V,  and  V x  genes  (31).  Indeed,  nmtated,  rearranged  V H 
genes were  identified  in  HRS  cells  from  patients  2  and  7 
that also harbored  unmutated,  out-of-frame V~  gene  rear- 
rangements (Table 3). 
The frequency of somatic mutations in V H genes ampli- 
fied  from HR.S  cells  varied  from 2.2  to  19.6%  (Table  3). 
On average, HRS cells  showed 10.7% somatic mutation in 
rearranged V H genes.  This contrasts to an average of 4  and 
2%  in  human  class-switched  IgG  +  and  lgM +  memory B 
cells  (21, 22, 29). The significantly higher average nmtation 
frequency  of the  clonal  Ig gene  rearrangements  amplified 
from H1LS cells  as compared to the nmtation frequency of 
normal human B  cells  is a further strong argument against a 
potential  contamination  of the  isolated  HRS  cells  by sur- 
rounding B  cells. 
The finding of V  gene rearrangements  and somatic mu- 
tations  in  HRS  cells  allows  one  not  only  to  assign  these 
cells  to  the  B  lineage  but  also  to  determine  the  develop- 
mental stage of the B  cell that was the precursor of the tu- 
mor clone.  Because  the process  of somatic hypemmtation 
appears  to be  restricted  to B  cells  undergoing proliferation 
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(18),  the finding of somatic mutations in the VH genes am- 
plified from HRS  cells  suggests  that  HRS  cells  originate 
from GC B  cells  or their progeny.  In retrospect,  this  also 
holds  true for two previously published cases  of HD  (NS 
and MC)  (13).  At that time, the limited knowledge of the 
human  VH  gene  locus  did  not  allow  us  to  identify  with 
confidence  somatic mutations  in  the  VH  gene  rearrange- 
ments  carried  by the  corresponding  HRS  cells.  Further- 
more,  the  presence  of two  nonfunctional  V.  gene  rear- 
rangements in the  case  of MC  HD led  us suspect that  in 
this instance the HRS cells  originated from an early B  cell 
progenitor that had failed to carry out a functional VH gene 
rearrangement on either of its two IgH alleles  (13).  How- 
ever, when we reanalyzed those sequences with the present 
knowledge  of the  human  IgH locus,  it became clear that 
the rearranged VH genes of both cases harbor somatic mu- 
tations (with a frequency of 2 and 3% in the two VH genes 
from the case ofMC HD and 16% in the case ofNS HD). 
Thus, also in these cases the HRS cells appear to be derived 
from GC B cells or their progeny. 
Strikingly,  we  observe  in  several instances  in-frame  V 
gene  rearrangements  that  were  apparently  rendered  non- 
functional by somatic mutation,  In this study, stop codons 
generated by somatic mutation were seen in three of nine 
cases from which  Ig gene rearrangements could be ampli- 
fied (VH genes in patients 8 and  10  and the Vx gene from 
patient 2). The situation in patient 8 is particularly informa- 
tive, because two VH gene rearrangements were amplified 
from the HRS cells, excluding the presence of a potentially 
functional VH gene on the second allele.  Similary, the HRS 
cells  from the MC  HD patient in our previous study (13) 
carried  a  nonproductively  rearranged  VHD~H  rearrange- 
ment in  addition  to  an  in-frame  one,  the  latter  rendered 
nonfunctional by a stop codon in CDRIII. In light of the 
other cases, it seems straightforward to assign the introduc- 
tion of this stop codon to somatic hypermutation as well. 
Under physiological conditions,  GC B  cells are strongly 
selected for the expression of high-affinity antibodies. Only 
cells fulfilling this criterion are allowed to persist in the GC 
microenvironment and to finally leave it in  order to join 
the pool of memory B  cells  (41).  Thus, B  cells bearing V 
gene  rearrangements  rendered  nonfunctional  by  somatic 
hypermutation can only occur within GC and cannot repre- 
sent  postgerminal  center  cells.  This  suggests  that  at  least 
those HRS cells  that carry such a rearrangement originate 
from precursor  cells  that  underwent  a  transforming event 
either before  their  entry  into  or within  a  GC,  such  that 
they escaped apoptotic death in the absence of antigenic se- 
lection.  This may also  hold true for those  cases  of HD in 
which we failed to detect mutations in V  gene rearrange- 
ments that would preclude Ig expression. With one excep- 
tion (14), we did not detect potentially functional, in-frame 
rearrangements for both H  and L  chain V  regions in any 
HRS cell.  In addition, in cases of potentially functional re- 
arrangements, we might have missed deleterious mutations 
outside  the  region  that  was  amplified.  And  perhaps most 
importantly, even if still able to express lg, a precursor cell 
might lose its ability to bind antigen through somatic muta- 
tion of its antibody-binding site.  The high load of somatic 
mutations in a large fraction of HRS cells goes well along 
with these possibilities.  Independence  of selection for ex- 
pression of functional surface Ig might also result in down- 
regulation of Ig expression in cases in which V  gene rear- 
rangements  were  not  rendered  nonfunctional  because  of 
crippling mutations as well. 
HRS Cell Progenitor Generation: A  Scenario.  In  light  of 
the molecular data presented above, a hypothetical unifying 
scenario of the pathogenesis of HD can be envisioned.  In 
this  scenario,  the  key feature  of the  progenitor  cell from 
which the HRS cells derive is that it survives in the GC, al- 
though,  because of somatic mutation,  it has lost its ability 
to be selected by an appropriate antigen--a prerequisite for 
normal  B  cells  to  survive  in  the  GC  microenvironment. 
Thus, in contrast to most other B  cell lymphomas (2),  the 
HRS cells in HD are independent  of surface Ig expression 
and  indeed  have usually been  found  not  to  express anti- 
body (3, 5). In this respect, classical HD is the true counter- 
part of follicular lymphoma, which  also  originates from a 
GC cell,  but in this case a cell that still  depends on signals 
through  its  antigen  receptor  (42).  Consistent  with  its  GC 
origin, follicular lymphoma is characterized by ongoing so- 
matic  hypermutation  (42),  whereas  the  process  of hyper- 
mutation  is  largely  abrogated  in  HRS  cells  (Fig.  2  and 
Table 3).  This latter finding may indicate that somatic hy- 
permutation  requires  triggering  of the  cell  through  its  Ig 
receptor.  Alternatively,  abrogation of somatic hypermuta- 
tion in HRS cells might be due to the disruption of the GC 
microenvironment (considered to be necessary for the pro- 
cess of somatic hypermutation) during tumor expansion. 
Which transforming event has hit the HRS cell progeni- 
tor such that it survives in the  absence of antigenic selec- 
tion? It seems reasonable to think that this event should re- 
sult in the premature upregulation of the gene that is known 
to protect GC cells from apoptosis, namely, bcl-2 (43);  in- 
deed,  in  a large fraction  of HD,  HRS  cells  express bcl-2 
protein  (44,  45).  It is an intriguing possibility that protec- 
tion  of the  HRS  cell  progenitor  from apoptosis  through 
bcl-2 upregulation  might be accomplished by EBV infec- 
tion: EBV has been detected in more than half of the cases 
of classical HD, where it is found in virtually all HRS cells 
(3, 46). Significantly, EBV-harboring HRS cells commonly 
express the LMP-1 gene (46)  (all five EBV-positive cases in 
Table 1), which is known to upregulate expression ofbcl-2 
(47). 
In this picture of the early events in the pathogenesis of 
HD,  many questions  remain  unanswered.  Thus,  it  is  not 
clear whether  HRS  cells  develop  from a  progenitor  that 
had  been infected  by EBV  before  entry  into  the  GC  (in 
EBV-positive individuals the frequency of infected B  cells 
is in the order of 10 -5) (48) or EBV infection takes place in 
the  GC  itself.  It  also  remains  to  be  resolved whether  in 
cases  of EBV-negative  HRS  cells  other  mechanisms  of 
transformation are involved or EBV has still played a role, 
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rescue  of "failed"  GC  cells from  apoptosis can  only be  a 
first step in the series of events that finally leads to the de- 
velopment of HD.  GC cells rescued from apoptosis might 
continue  to  proliferate in  the  GC  microenvironment  and 
further accumulate somatic mutations, thus being at an in- 
creased risk to  acquire  further  genetic  changes  leading to 
malignancy. Such events may be promoted in GC ceils by 
the occasional failure to properly target somatic hypermu- 
tation to rearranged antibody V  region genes. 
Taken together, this analysis demonstrates that in at least 
the major fraction of cases of classical HD,  HRS cells rep- 
resent a  clonal population of B  lineage cells. The presence 
of a high load of somatic mutations, together with the de- 
tection  of  mutations  rendering  Ig  genes  nonfunctional, 
suggests that  these ceils originate from a precursor located 
within the GC, which because of crippling somatic muta- 
tions had lost its ability to be selected by antigen  and was 
prevented from apoptosis by a transforming event. 
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